Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts

Blood (2007) 110 (10): 3744–3752.

https://doi.org/10.1182/blood-2007-05-093294

Published: 2007

Includes: Supplemental data

Journal Articles

MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation.

Sonia Vallet, MD, Noopur Raje, MD, Kenji Ishitsuka, MD, Teru Hideshima, MD, Klaus Podar, MD, Petter Veiby, Iris Breitkreutz, MD, Tanyel Kizeltepe, PHD, Hiroshi Yasui, MD, Enrique M. Ocio, MD, Norihiko Shiraishi, Marco Ladetto, MD, Mario Boccadoro, MD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 1636.

https://doi.org/10.1182/blood.V108.11.1636.1636

Published: 2006

Journal Articles

p38MAPK Inhibitor LSN2322600 Modulates the Bone Marrow Microenvironment and Inhibits Osteoclastogenesis in Multiple Myeloma.

Kenji Ishitsuka, MD, PhD, Teru Hideshima, M.D., Ph.D., Paola Neri, M.D., Ph.D., Sonia Vallet, M.D., Ph.D., Norihiko Shiraishi, Ph.D., Noopur Raje, M.D., Zhenxin Shen, M.D., Ph.D., Tanyel Kiziltepe, Ph.D., Enrique M. Ocio, M.D., Ph.D., Klaus Podar, M.D., Ph.D., Dharminder Chauhan, Ph.D., Nikhil Munshi, M.D., Robert M. Campbell, Ph.D., Alfonso De Dios, Ph.D., Chuan Shih, Ph.D., James J. Starling, Ph.D., Kazuo Tamura, M.D., Ph.D., Kenneth C. Anderson, M.D.

Blood (2006) 108 (11): 5042.

https://doi.org/10.1182/blood.V108.11.5042.5042

Published: 2006

Journal Articles

Didox Induced Apoptosis Occurs by Inhibiting DNA Synthesis and Repair Via Down-Regulation of Ribonucleotide Reductase M1 in Multiple Myeloma (MM).

Noopur Raje, MD, Shaji Kumar, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Hiroshi Yasui, MD, PhD, Norihiko Shiraishi, PhD, Tanyel Kiziltepe, PhD, Shweta Chhetri, BS, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 5153.

https://doi.org/10.1182/blood.V106.11.5153.5153

Published: 2005

Journal Articles

The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).

Noopur Raje, MD, Shaji Kumar, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Hiroshi Yasui, MD, PhD, Yu-Tzu Tai, PhD, Norihiko Shiraishi, PhD, Tanyel Kizeltepe, PhD, Shweta Chhetri, BS, Sonia Vallet, MD, Robert L. Schlossman, MD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 3380.

https://doi.org/10.1182/blood.V106.11.3380.3380

Published: 2005

Journal Articles

R-Etodolac and a Novel Indole-Pyran Structural Analog, SDX-308, Induce Cytotoxicity and Overcome Drug Resistance in Multiple Myeloma.

Hiroshi Yasui, Teru Hideshima, Paola Neri, Janice Jin, Tanyel Kiziltepe, Norihiko Shiraishi, Kenji Ishitsuka, Catley P. Laurence, Noopur Raje, Klaus Podar, Pierfrancesco Tassone, Dharminder Chauhan, Paul G. Richardson, Lorenzo M. Leoni, Sarath Kanekal, Gary T. Elliott, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2005) 106 (11): 1580.

https://doi.org/10.1182/blood.V106.11.1580.1580

Published: 2005

Journal Articles

Targeting Src- Family Kinase Activation and Downstream Molecular Events To Overcome MM Cell Growth, Survival, and Drug- Resistance.

Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Dean Abtahi, BS, Marc S. Raab, MD, Hiroshi Yasui, MD, PhD, Kenji Ishitsuka, MD, PhD, Norihiko Shiraishi, PhD, Laurence P. Catley, MD, Martin Sattler, PhD, Noopur Raje, MD, Teru Hideshima, MD, PhD, Dharminder Chauhan, JD, PhD

Blood (2005) 106 (11): 1583.

https://doi.org/10.1182/blood.V106.11.1583.1583

Published: 2005

Journal Articles

JS-K, a GST-Activated Nitric Oxide Generator, Induces Apoptosis and Overcomes In Vitro Drug Resistance in Multiple Myeloma Cells.

Tanyel Kiziltepe, PhD, Kenji Ishitsuka, MD, PhD, Teru Hideshima, MD, PhD, Noopur Raje, MD, Norihiko Shiraishi, PhD, Hiroshi Yasui, MD, PhD, Laurence Catley, MD, Dharminder Chauhan, PhD, Joseph E. Saavedra, PhD, Larry K. Keefer, PhD, Paul J. Shami, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 1593.

https://doi.org/10.1182/blood.V106.11.1593.1593

Published: 2005

Journal Articles

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

Kenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, Noopur Raje, Shaji Kumar, Hiromasa Hideshima, Norihiko Shiraishi, Hiroshi Yasui, Aldo M. Roccaro, Paul Richardson, Klaus Podar, Steven Le Gouill, Dharminder Chauhan, Kazuo Tamura, Jack Arbiser, Kenneth C. Anderson

Blood (2005) 106 (5): 1794–1800.

https://doi.org/10.1182/blood-2005-01-0346

Published: 2005

Journal Articles

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

Noopur Raje, Shaji Kumar, Teru Hideshima, Aldo Roccaro, Kenji Ishitsuka, Hiroshi Yasui, Norihiko Shiraishi, Dharminder Chauhan, Nikhil C. Munshi, Simon R. Green, Kenneth C. Anderson

Blood (2005) 106 (3): 1042–1047.

https://doi.org/10.1182/blood-2005-01-0320

Published: 2005

Journal Articles

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma

Hiroshi Yasui, Teru Hideshima, Makoto Hamasaki, Aldo M. Roccaro, Norihiko Shiraishi, Shaji Kumar, Pierfrancesco Tassone, Kenji Ishitsuka, Noopur Raje, Yu-Tzu Tai, Klaus Podar, Dharminder Chauhan, Lorenzo M. Leoni, Sarath Kanekal, Gary Elliott, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2005) 106 (2): 706–712.

https://doi.org/10.1182/blood-2005-02-0838

Published: 2005

Journal Articles

Azaspirane ( N-N -diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo

Makoto Hamasaki, Teru Hideshima, Pierfrancesco Tassone, Paola Neri, Kenji Ishitsuka, Hiroshi Yasui, Norihiko Shiraishi, Noopur Raje, Shaji Kumar, Donald H. Picker, Gary S. Jacob, Paul G. Richardson, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2005) 105 (11): 4470–4476.

https://doi.org/10.1182/blood-2004-09-3794

Published: 2005

Journal Articles

Bortezomib Targets Multiple Myeloma Endothelial Cells.

Aldo M. Roccaro, M.D., Teru Hideshima, M.D.Ph.D, Noopur Raje, M.D., Shaji Kumar, M.D., Kenji Ishitsuka, M.D., Hiroshi Yasui, M.D., Norihiko Shiraishi, M.D., Makoto Hamasaki, M.D., Paul G. Richardson, M.D., Kenneth C. Anderson, M.D.

Blood (2004) 104 (11): 4903.

https://doi.org/10.1182/blood.V104.11.4903.4903

Published: 2004

Journal Articles

Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.

Makoto Hamasaki, Teru Hideshima, Pierfrancesco Tassone, Paola Neli, Kenji Ishitsuka, Masaharu Akiyama, Toshiaki Hayashi, Hiroshi Yasui, Norihiko Shiraishi, Dharminder Chauhan, Constantine Mitsiades, Klaus Podar, Deepak Gupta, Donald H. Picker, Gary S. Jacob, Paul G. Richardson, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2004) 104 (11): 2401.

https://doi.org/10.1182/blood.V104.11.2401.2401

Published: 2004

Journal Articles

Anti-Myeloma Activity of Two Novel N-Substituted and Tetraflourinated Thalidomide Analogues.

Shaji Kumar, MD, Noopur Raje, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Aldo Roccaro, MD, Norihiko Shiraishi, MD, Makoto Hamasaki, MD, Hiroshi Yasui, MD, Nikhil C. Munshi, MD, William D. Figg, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 2406.

https://doi.org/10.1182/blood.V104.11.2406.2406

Published: 2004

Journal Articles

In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM).

Noopur Raje, MD, Shaji Kumar, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Aldo Roccaro, MD, Hiroshi Yasui, MD, Makoto Hamasaki, MD, Norihiko Shiraishi, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Simon R. Green, PhD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 3359.

https://doi.org/10.1182/blood.V104.11.3359.3359

Published: 2004

Journal Articles

Anti-Tumor Activity of a Novel Immunosuppressant FTY720 in Multiple Myeloma.

Hiroshi Yasui, Teru Hideshima, Aldo M. Roccaro, Norihiko Shiraishi, Makoto Hamasaki, Kenji Ishitsuka, Shaji Kumar, Noopur Raje, Guilan Li, Yu-Tzu Tai, Klaus Podar, Dharminder Chauhan, Kenneth C. Anderson

Blood (2004) 104 (11): 3456.

https://doi.org/10.1182/blood.V104.11.3456.3456

Published: 2004

Journal Articles

SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma.

Makoto Hamasaki, Teru Hideshima, Kenji Ishitsuka, Hiroshi Yasui, Norihiko Shiraishi, Shaji Kumar, Noopur Raje, Aldo M. Roccaro, Yu-Tzu Tai, Reshma Shiringarpure, Lorenzo Leoni, Sarath Kanekal, Gary Elliott, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2004) 104 (11): 3466.

https://doi.org/10.1182/blood.V104.11.3466.3466

Published: 2004

Journal Articles

Honokiol Overcomes Conventional Drug Resistance in Human Multiple Myeloma.

Kenji Ishitsuka, M.D., Ph.D, Teru Hideshima, M.D., Ph.D, Makoto Hamasaki, M.D., Ph.D, Raje Noopur, M.D., Ph.D, Kumar Shaji, M.D., Ph.D, Hiromasa Hideshima, Norihiko Shiraishi, Ph.D, Paul Richardson, M.D., Ph.D, Nikhil C. Munshi, M.D., Ph.D, Dharminder Chauhan, Ph.D, Jack Arbiser, M.D., Ph.D, Kenneth C. Anderson, M.D., Ph.D

Blood (2004) 104 (11): 1488.

https://doi.org/10.1182/blood.V104.11.1488.1488

Published: 2004

NARROW

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts

MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation.

p38MAPK Inhibitor LSN2322600 Modulates the Bone Marrow Microenvironment and Inhibits Osteoclastogenesis in Multiple Myeloma.

Didox Induced Apoptosis Occurs by Inhibiting DNA Synthesis and Repair Via Down-Regulation of Ribonucleotide Reductase M1 in Multiple Myeloma (MM).

The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).

R-Etodolac and a Novel Indole-Pyran Structural Analog, SDX-308, Induce Cytotoxicity and Overcome Drug Resistance in Multiple Myeloma.

Targeting Src- Family Kinase Activation and Downstream Molecular Events To Overcome MM Cell Growth, Survival, and Drug- Resistance.

JS-K, a GST-Activated Nitric Oxide Generator, Induces Apoptosis and Overcomes In Vitro Drug Resistance in Multiple Myeloma Cells.

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma

Azaspirane ( N-N -diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo

Bortezomib Targets Multiple Myeloma Endothelial Cells.

Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.

Anti-Myeloma Activity of Two Novel N-Substituted and Tetraflourinated Thalidomide Analogues.

In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or R-Roscovitine), in Multiple Myeloma (MM).

Anti-Tumor Activity of a Novel Immunosuppressant FTY720 in Multiple Myeloma.

SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma.

Honokiol Overcomes Conventional Drug Resistance in Human Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only